Compare Merck & Co., Inc. (MRK) vs Invesco NASDAQ 100 ETF (QQQM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Invesco NASDAQ 100 ETF — how do they compare? Merck & Co., Inc. trades at $146.21 (market cap $351.28B), while Invesco NASDAQ 100 ETF trades at $309.36 (market cap $113.40B). The key difference: Merck & Co., Inc. is far larger — about 3.1× Invesco NASDAQ 100 ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Invesco NASDAQ 100 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Invesco NASDAQ 100 ETF for 54 Days on average.
| MRK | QQQM | |
|---|---|---|
Market Cap | $351.28B | $113.40B |
Volume | 7,969,665 | 2,866,236 |
Sector | Health | Broad Market / Factor |
52-Week High | $156.43 | $312.76 |
52-Week Low | $82.49 | $229.87 |
Typical Hold Time | 98 Days | 54 Days |
Enterprise Value | $398.04B | — |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
QQQM (Invesco NASDAQ 100 ETF) trades at $309.27, down 0.88% on the day, with a bullish technical signal from moving averages. The ETF tracks the NASDAQ-100 index with a low 0.15% expense ratio. Recent institutional buying includes QRG Capital Management increasing its position by 207.5% during Q2 2026. Technical indicators show support at $305 and resistance at $311, with neutral oscillator readings suggesting balanced momentum.
The outlook remains positive given the NASDAQ-100's growth exposure and cost efficiency versus QQQ. Risks include market concentration in technology stocks and potential volatility from macroeconomic factors. Institutional accumulation and favorable expense structure support long-term positioning, though investors should monitor index composition changes and broader market trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →
